Association of Proton Pump Inhibitor Prophylaxis on Clinical Outcome in Acute Ischemic Stroke in China: A Multicenter Retrospective Cohort Study
by
,
Lei Fang
1,2,†, 
Wansi Zhong
1,†,
Xiaoxian Gong
1,
Zhicai Chen
1,
Yi Chen
1,
Shenqiang Yan
1 and
Min Lou
1,* 1
Department of Neurology, The Second Affiliated Hospital of Zhejiang University, School of Medicine, Hangzhou 310009, China
2
Department of Neurology, Zhejiang General Team Hospital of Chinese People’s Armed Police Force, Hangzhou 310051, China
*
Author to whom correspondence should be addressed.
†
These authors contributed equally to this work.
J. Clin. Med. 2022, 11(23), 6881; https://doi.org/10.3390/jcm11236881
Submission received: 23 October 2022
/
Revised: 9 November 2022
/
Accepted: 15 November 2022
/
Published: 22 November 2022
(This article belongs to the Section Clinical Neurology)
Abstract
:Background: Overtreatment with proton pump inhibitors (PPIs) in acute ischemic stroke (AIS) patients continues to grow. We aimed to investigate the frequency of PPI prophylaxis without an appropriate indication in AIS patients in China and clarify the association between PPI prophylaxis and long-term prognosis. Methods: Based on a multicenter stroke registry database, neurological outcomes, stroke events, recurrent ischemic strokes, and all-cause death were compared between patients with and without PPI prophylaxis. Results: A total of 4542 AIS were included, and 3335 (73.4%) received PPI prophylaxis. Patients with PPI prophylaxis were more likely to have a poor outcome at 1 year than those without PPI prophylaxis (33.3% vs. 25.8%, OR 1.321; 95% CI 1.102–1.584; p = 0.003). No significant differences were found in all-cause death, stroke event, or recurrent ischemic stroke at 1 year between the two groups. After propensity score matching, PPI prophylaxis was still independently associated with a higher rate of poor outcome (30.9% vs. 25.8%, OR 1.432; 95% CI 1.151–1.780; p = 0.001). Sensitivity analysis also showed that PPI prophylaxis increased the rate of a poor outcome in minor strokes or at different durations of PPI prophylaxis. Conclusions: Approximately 3/4 of AIS patients were given PPI prophylaxis during hospitalization, which was associated with a poor long-term outcome.
1. Introduction
China faces the greatest challenge from stroke in the world [1]. Recurrence is particularly challenging as the risk of recurrent stroke was estimated at 11.1% and 26.4% at first and five years after stroke onset, respectively [2]. To prevent recurrent stroke or stroke progression in acute ischemic stroke (AIS) patients, antiplatelet therapy is commonly used, with subsequent addition of proton pump inhibitors (PPIs) to prevent against potential gastrointestinal disease [3,4]. This is because randomized trials have shown that antiplatelets increase the risk of major gastrointestinal bleeds (GIB), while PPIs could reduce low-dose aspirin-associated gastrointestinal ulcers and bleeding by 70–90% [5].
Concerns have been raised about the adverse effects of PPI use. It was reported that, in the general population, PPI use alone increased the risk of a first-time ischemic stroke by 0.04% [6]. PPI use was also associated with an increased risk of cardiovascular events by 7.7% in aspirin-treated patients diagnosed with a first-time myocardial infarction [7].
PPI use still continues to grow every year in almost all western and eastern countries. It has been reported that 40% of patients used PPIs for a non-registered indication in the Netherlands, and more than 50% of patients failed to meet proper indications for PPI therapy in Colorado, calling into question the role of PPI misuse [8,9]. Indeed, PPIs prescribed without indication have been previously reported to range from 27% to 71% [10,11,12,13]. Therefore, we aimed to investigate the frequency of PPI prophylaxis in AIS patients and try to clarify the association of PPI prophylaxis with long-term prognosis among AIS patients in China.
2. Materials and Methods
2.1. Study Subjects
We retrospectively reviewed our prospectively collected database for consecutive patients with AIS who were admitted between December 2015 to December 2018 from 10 stroke centers. The data was from an automated enrollment computer-based online database of acute stroke patients for stroke management quality evaluation II (CASE II) registry (NCT 04487340), a longitudinal record of care for stroke inpatients. Patients aged ≥18 years and diagnosed with an AIS within 14 days of onset were included. We excluded patients who (1) had a pre-stroke modified Rankin scale (mRS) score ≥ 2, (2) had appropriate guideline-recommended indications for PPI use [14], and (3) had no follow-up mRS score at 1 year.
2.2. Ethics Statement
The Ethics Committee of the Second Affiliated Hospital of Zhejiang University, School of Medicine, approved the protocol. The clinical investigation was conducted according to the principles expressed in the Declaration of Helsinki. Thus, patient information was de-identified and anonymized and the informed consent requirement was waived by the Ethics Committee of the Second Affiliated Hospital of Zhejiang University, School of Medicine.
2.3. Clinical Data
Patient characteristics were recorded from the registry database, including demographic, clinical, and laboratory data including prescription of PPIs, age, gender, history of smoking, history of stroke, and comorbid conditions such as hypertension, diabetes, atrial fibrillation, hyperlipidemia, a baseline National Institutes of Health Stroke Scale (NIHSS) score, baseline systolic blood pressure (SBP), baseline diastolic blood pressure (DBP), blood glucose, and intravenous thrombolysis (IVT). Minor stroke was defined as a baseline NIHSS ≤ 5 [15]. PPI prophylaxis was defined as PPI use for AIS patients without appropriate indication during hospitalization. Non-PPI prophylaxis was defined as no PPI use during hospitalization. PPIs included omeprazole, pantoprazole, lansoprazole, esomeprazole, and rabeprazole.
All patients were followed up at 1 year by certified external clinical evaluators during a standardized telephone interview. All telephone interviews were recorded and traceable.
Clinical outcome was assessed with the mRS score and dichotomized into good outcome (mRS ≤ 2) and poor outcome (mRS > 2) at discharge and 1 year. Stroke events were defined as fatal or non-fatal acute events that fulfilled the typical symptoms of stroke (that is, people presenting clinical signs and symptoms suggestive of subarachnoid hemorrhage, intracerebral hemorrhage, or ischemic stroke) [16]. Recurrent ischemic stroke was defined as a new focal neurological deficit of vascular origin lasting > 24 h and without hemorrhage on computed tomography or MRI of the brain, which was included in the stroke event [17].
2.4. Statistical Analysis
Clinical characteristics were summarized as mean ± SD or median (25th–75th percentile) for quantitative variables and as proportions for categorical variables. The chi-square test was used to compare the dichotomous variables between groups, whereas for independent samples a two-tailed t-test or a Mann–Whitney U test was for the continuous variables. Variables with a p-value ≤ 0.05 in univariate analyses were entered into the binary logistic regression model.
Propensity score-matched (PSM) analysis was used to minimize potential imbalances in the distribution of potential confounders between PPI prophylaxis and non-PPI prophylaxis. For matching, we used a structured, iterative propensity score model with the inclusion of age, history of smoking, hyperlipidemia, and the baseline NIHSS score to maximize the balance in the distribution of possible confounders between the two aforementioned groups. The corresponding propensity score was calculated for each subject, and a nearest-neighbor matching algorithm with a 1:1 allocation was subsequently implemented to match eligible patients with PPI prophylaxis and non-PPI prophylaxis. We used a conservative calliper size of 0.2 SDs of the logit of the PSM to provide adequate matching. Univariate analysis and binary logistic regression were repeated after propensity score matched analysis. To assess whether the results were influenced by the duration of PPI prophylaxis and baseline NIHSS, sensitivity analyses were performed by repeating the primary analysis between AIS patients with PPI prophylaxis lasting more than seven days and less than seven days (including non-PPI prophylaxis) and minor stroke patients. We also repeated the primary analysis after matching for all risk factors. All statistical analyses were performed using SPSS Version 22.0 (IBM, Armonk, NY, USA). A p-value < 0.05 was considered statistically significant.
3. Results
A total of 5860 AIS patients were included. As the flow chart of patient selection shows (Figure 1), the final analysis includes 4542 patients after excluding patients who had a pre-stroke mRS score > 2 (n = 141), had appropriate indications for PPI use (n = 214), and had no follow-up mRS score at 1 year (n = 963). Of the included patients, 3335 (73.4%) patients received PPI prophylaxis. The mean age was 67.3 ± 12.9 years, and 1311 (39.3) patients were women. The median NIHSS score was 3 (1–6). In total, 1561 (34.4%) achieved a poor outcome at discharge. During the 1-year follow-up, 296 (6.5%) patients suffered a stroke event, 289 (6.4%) patients had a recurrent ischemic stroke, and 1421 (31.3%) patients had a poor outcome.
3.1. Unmatched Analysis
As Table 1 shows, patients with PPI prophylaxis were younger, had a higher rate of smoking, and had a higher baseline NIHSS score than patients not receiving PPI prophylaxis. A higher rate of post-stroke pneumonia (14.0% vs. 8.1%, p < 0.001), gastrointestinal bleeding (1.5% vs. 0.1%, p < 0.001), poor outcome at discharge (36.4% vs. 28.8%, p < 0.001), and poor outcome at 1 year (33.3% vs. 25.8%, p < 0.001) was found among patients with PPI prophylaxis compared to non-PPI prophylaxis (Table 2). There were no significant differences in all-cause death, recurrent ischemic stroke, or stroke event at 1 year between the two groups (p >0.05). Binary logistic regression analysis revealed that PPI prophylaxis was associated with a higher rate of poor outcome at 1 year (OR 1.321; 95% CI 1.102–1.584; p = 0.003) (Table 2) but not with a higher rate of poor outcome at discharge (OR 1.052; 95% CI 0.880–1.257; p = 0.577) (Table S1). In addition, gastrointestinal bleeding was not significantly associated with poor outcome at 1 year (OR 1.554; 95% CI 0.730–3.305; p = 0.253). Post-stroke pneumonia was significantly associated with poorer outcomes (OR 2.285; 95% CI 2.015–3.308; p < 0.001).
3.2. Propensity-Matched Analysis
For the analysis of propensity score matching, we balanced baseline factors including age, history of smoking, hyperlipidemia, and baseline NIHSS score, resulting in 1207 patients with PPI prophylaxis and 1207 patients without PPI prophylaxis.
Univariate and binary logistics models were repeated to identify independent predictors for poor outcome. Binary logistic regression analysis revealed that PPI prophylaxis was independently associated with a higher rate of poor outcome at 1 year (30.9% vs. 25.8%, OR 1.432; 95% CI 1.151–1.780; p = 0.001) (Table 1 and Table 2).
3.3. Sensitivity Analysis and Subgroup Analysis
A sensitivity analysis was conducted in minor stroke patients and AIS patients with different durations of PPI prophylaxis, showing that PPI prophylaxis was still independently associated with a poor outcome at 1 year (Table 3 and Tables S2–S4). After matching for age, history of smoking, hypertension, diabetes, atrial fibrillation, hyperlipidemia, and baseline NIHSS score, the results were consistent with the main analysis (Tables S5 and S6).
Subgroup analysis (Figure 2) shows that the association between PPI prophylaxis and poor outcome at 1 year was not found in patients with an age < 65 years, diabetes, atrial fibrillation, hyperlipidemia, history of stroke, receiving intravenous thrombolysis, anticoagulant therapy, and non-aspirin user.
4. Discussion
In this study, the proportion of AIS patients receiving PPI prophylaxis was 73.4%. Both unmatched and propensity score analyses revealed that PPI prophylaxis increased the odds of a poor outcome one year after an AIS.
The use of PPI in AIS patients should attract enough attention in China, as the rate of PPI prophylaxis in our study was higher than in previous studies (27–71%). Previous studies recommended the use of PPIs for stress ulcer prophylaxis in patients at high risk of gastrointestinal bleeding [18]. However, Mohammad et al. found that over 86% of patients in the general medical ward used PPIs inappropriately [19]. Ntaios et al. reported that 81.2% of hospitalized patients in an internal medicine department had no indications for the administration of PPIs, according to national guidelines [20]. The most common reasons for overuse of PPIs are the prevention of gastro-duodenal ulcers in patients without risk factors, stress ulcer prophylaxis in non-intensive care units, anticoagulant and antiplatelet treatment in patients without risk of gastric injury, and the overtreatment of functional dyspepsia [21]. In general, PPIs are perceived by clinicians as a harmless and relatively inexpensive preventative therapy for any digestive problem or as essential protection against possible drug-related gastric problems, eventually resulting in the overuse of PPIs in clinical practice.
Evidence suggests that taking PPIs is associated with a small excess of cause-specific mortality, including death due to cardiovascular disease, chronic kidney disease, and upper gastrointestinal cancer [22]. Importantly, in the current study, PPI prophylaxis was also found to increase the rate of poor outcomes after one year. Even sensitivity analysis revealed such an association in minor stroke patients, excluding the possibility of confounding by indication. There are several potential mechanisms. (1) Long term exposure to PPIs increases oxidative stress, impairs endothelial function, and accelerates human endothelial senescence, which might lead to increased risk of cardiovascular morbidity and mortality [22,23]. (2) PPIs may inhibit the activity of nitric oxide (NO) synthase and facilitate the reduction of NO, while endothelium-derived NO is an important endogenous mediator of cerebral blood flow [24]. Plasma NO levels were significantly lower in stroke patients than in healthy volunteers, and studies have revealed that decreased plasma NO was associated with an unfavorable outcome in non-lacunar stroke patients [25]. (3) The application of PPIs could increase the risk of post-stroke pneumonia, which was associated with a poor long-term functional outcome [26,27]. Post-stroke pneumonia may be a contributor to the poor outcome in AIS patients with receiving prophylactic PPI.
Guidelines recommend PPI prophylaxis in patients with a high risk of GIB [28]. We noticed that, from the results of subgroup analysis, most of the groups that did not reveal the association of PPI prophylaxis with poor outcome after one year were the ones that included patients who had a high risk of GIB. For example, it is commonly recognized that patients receiving antithrombotic agents experience an increased risk of GIB [29,30]. Blood glucose in patients with GIB was 0.8 mmol/L higher than that in patients without GIB. Patients with atrial fibrillation, hypertension, and a history of transient ischemic attack increased their risk of GIB by 8.5%, 5.3%, and 6.9%, respectively [31,32,33,34,35]. It was reported that GIB after IVT occurred in 5.3% of patients [36]. Therefore, our finding strongly supports that PPI prophylaxis should be appropriately used in patients with a high risk of GIB in clinical practice rather than all AIS patients, as guidelines for PPI prophylaxis recommend.
This is the first study to explore the impact of PPI prophylaxis on the long-term neurological outcome of AIS. Our results suggested that the inappropriate use of PPIs should be discouraged in order to decrease the potential for poor outcomes, which have public health implications, considering the high prevalence of PPI prophylaxis. Our findings also highlight the importance of risk evaluation for GIB before PPI prophylaxis.
Our study has several limitations. First, our study had a retrospective design and a potential risk of selection bias, although we prospectively collected data using a multicenter stroke registry, and we have attempted to control for confounding using propensity score matched analysis to reduce the biases of the results. Second, the duration of PPIs and the usage of PPIs after discharge were not recorded exactly, which may have a different effect on outcome, though we have conducted a sensitivity analysis in AIS patients with PPI prophylaxis for more than seven days and less than seve days (including non-PPI prophylaxis). Third, we did not evaluate the impact of different types of PPIs. It is not clear whether the pharmacokinetics and pharmacodynamics of PPIs would change their underlying mechanisms. Finally, although almost 75% of patients in this study had a minor stroke, data on treatment in an intensive care unit and controlled mechanical ventilation were not available, which may influence the stroke outcome.
5. Conclusions
PPI prophylaxis in hospitalized AIS patients was associated with higher rates of poor long-term outcomes. Rigorous assessments of PPI prophylaxis for those with a high risk of major gastrointestinal bleeds are warranted.
Supplementary Materials
The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/jcm11236881/s1, Table S1: Univariate comparison and multivariate analysis for poor outcome at discharge in unmatched and propensity-matched patients; Table S2: Demographic and clinical characteristics of the study population for long-term outcomes between AIS patients with PPI prophylaxis more than seven days and less than seven days; Table S3: Demographic and clinical characteristics of minor acute ischemic stroke; Table S4: Univariate comparison and multivariate analysis for poor outcome after one year in unmatched and propensity-matched minor acute ischemic stroke; Table S5: Demographic and Clinical Characteristics of Study Population (Matching for age, history of smoking, hypertension, diabetes, atrial fibrillation, hyperlipidemia, and baseline NIHSS score); Table S6: Univariate comparison and multivariate analysis for poor outcome at 1 year in unmatched and propensi-ty-matched patients (Matching for age, history of smoking, hypertension, diabetes, atrial fibrillation, hyperlipidemia, and baseline NIHSS score).
Author Contributions
M.L.: conceptualization; data curation; funding acquisition; investigation; project administration; resources; supervision; writing—review and editing. L.F.: conceptualization; data curation; formal analysis; methodology; writing—original draft. W.Z.: conceptualization; data curation; formal analysis; methodology; validation; writing-original draft. X.G.: methodology; supervision; validation; writing—original draft. Z.C.: conceptualization; data curation; formal analysis; supervision; validation. Y.C.: data curation; formal analysis; supervision; writing—review and editing. S.Y.: data curation; methodology; supervision. All authors contributed to the article and approved the submitted version. All authors have read and agreed to the published version of the manuscript.
Funding
This study was supported by the National Natural Science Foundation of China (81971101, 82171276; Min Lou), and the Science Technology Department of Zhejiang Province (2018C04011; Min Lou). The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Institutional Review Board Statement
The study was conducted according to the guidelines of the Declaration of Helsinki. The study was approved by the local human ethics committee (YAN-2018-095).
Informed Consent Statement
Given that patient information was de-identified and anonymized, the informed consent requirement was waived.
Data Availability Statement
The raw data supporting the conclusions of this article will be made available by the authors on reasonable request, without undue reservation (contact via [email protected]).
Acknowledgments
We thank the patients for their involvement and the investigators for their diligence.
Conflicts of Interest
All authors have completed the ICMJE uniform disclosure form. The authors have no conflict of interest to declare.
References
- GBD 2016 Stroke Collaborators. Global, regional, and national burden of stroke, 1990–2016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019, 18, 439–458. [Google Scholar] [CrossRef] [Green Version]
- Mohan, K.M.; Wolfe, C.D.; Rudd, A.G.; Heuschmann, P.U.; Kolominsky-Rabas, P.L.; Grieve, A.P. Risk and cumulative risk of stroke recurrence: A systematic review and meta-analysis. Stroke 2011, 42, 1489–1494. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Chen, Z.M.; Sandercock, P.; Pan, H.C.; Counsell, C.; Collins, R.; Liu, L.S.; Xie, J.X.; Warlow, C.; Peto, R. Indications for early aspirin use in acute ischemic stroke : A combined analysis of 40 000 randomized patients from the chinese acute stroke trial and the international stroke trial. On behalf of the CAST and IST collaborative groups. Stroke 2000, 31, 1240–1249. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kimmey, M.B. Cardioprotective effects and gastrointestinal risks of aspirin: Maintaining the delicate balance. Am. J. Med. 2004, 117 (Suppl. 5A), 72S–78S. [Google Scholar] [CrossRef] [PubMed]
- Mo, C.; Sun, G.; Lu, M.L.; Zhang, L.; Wang, Y.Z.; Sun, X.; Yang, Y.S. Proton pump inhibitors in prevention of low-dose aspirin-associated upper gastrointestinal injuries. World J. Gastroenterol. 2015, 21, 5382–5392. [Google Scholar] [CrossRef]
- Wang, Y.F.; Chen, Y.T.; Luo, J.C.; Chen, T.J.; Wu, J.C.; Wang, S.J. Proton-pump inhibitor use and the risk of first-time ischemic stroke in the general population: A nationwide population-based study. Am. J. Gastroenterol. 2017, 112, 1084–1093. [Google Scholar] [CrossRef]
- Charlot, M.; Grove, E.L.; Hansen, P.R.; Olesen, J.B.; Ahlehoff, O.; Selmer, C.; Lindhardsen, J.; Madsen, J.K.; Køber, L.; Torp-Pedersen, C.; et al. Proton pump inhibitor use and risk of adverse cardiovascular events in aspirin treated patients with first time myocardial infarction: Nationwide propensity score matched study. BMJ 2011, 342, d2690. [Google Scholar] [CrossRef] [Green Version]
- Van Vliet, E.P.; Otten, H.J.; Rudolphus, A.; Knoester, P.D.; Hoogsteden, H.C.; Kuipers, E.J.; Siersema, P.D. Inappropriate prescription of proton pump inhibitors on two pulmonary medicine wards. Eur. J. Gastroenterol. Hepatol. 2008, 20, 608–612. [Google Scholar] [CrossRef]
- Reid, M.; Keniston, A.; Heller, J.C.; Miller, M.; Medvedev, S.; Albert, R.K. Inappropriate prescribing of proton pump inhibitors in hospitalized patients. J. Hosp. Med. 2012, 7, 421–425. [Google Scholar] [CrossRef]
- Nardino, R.J.; Vender, R.J.; Herbert, P.N. Overuse of acid-suppressive therapy in hospitalized patients. Am. J. Gastroenterol. 2000, 95, 3118–3122. [Google Scholar] [CrossRef]
- Parente, F.; Cucino, C.; Gallus, S.; Bargiggia, S.; Greco, S.; Pastore, L.; Bianchi Porro, G. Hospital use of acid-suppressive medications and its fall-out on prescribing in general practice: A 1-month survey. Aliment. Pharmacol. Ther. 2003, 17, 1503–1506. [Google Scholar] [CrossRef] [PubMed]
- Gullotta, R.; Ferraris, L.; Cortelezzi, C.; Minoli, G.; Prada, A.; Comin, U.; Rocca, F.; Ferrara, A.; Curzio, M. Are we correctly using the inhibitors of gastric acid secretion and cytoprotective drugs? Results of a multicentre study. Ital. J. Gastroenterol. Hepatol. 1997, 29, 325–329. [Google Scholar] [PubMed]
- Schepisi, R.; Fusco, S.; Sganga, F.; Falcone, B.; Vetrano, D.L.; Abbatecola, A.; Corica, F.; Maggio, M.; Ruggiero, C.; Fabbietti, P.; et al. Inappropriate use of proton pump inhibitors in elderly patients discharged from acute care hospitals. J. Nutr. Health Aging 2016, 20, 665–670. [Google Scholar] [CrossRef] [PubMed]
- Savarino, V.; Dulbecco, P.; de Bortoli, N.; Ottonello, A.; Savarino, E. The appropriate use of proton pump inhibitors (PPIs): Need for a reappraisal. Eur. J. Intern. Med. 2017, 37, 19–24. [Google Scholar] [CrossRef] [PubMed]
- Yaghi, S.; Herber, C.; Boehme, A.K.; Andrews, H.; Willey, J.Z.; Rostanski, S.K.; Siket, M.; Jayaraman, M.V.; McTaggart, R.A.; Furie, K.L.; et al. The association between diffusion MRI-defined infarct volume and NIHSS score in patients with minor acute stroke. J. Neuroimaging 2017, 27, 388–391. [Google Scholar] [CrossRef] [Green Version]
- Mons, U.; Müezzinler, A.; Gellert, C.; Schöttker, B.; Abnet, C.C.; Bobak, M.; de Groot, L.; Freedman, N.D.; Jansen, E.; Kee, F.; et al. Impact of smoking and smoking cessation on cardiovascular events and mortality among older adults: Meta-analysis of individual participant data from prospective cohort studies of the CHANCES consortium. BMJ 2015, 350, h1551. [Google Scholar] [CrossRef] [Green Version]
- Zhang, C.; Wang, Y.; Zhao, X.; Liu, L.; Wang, C.; Pu, Y.; Zou, X.; Pan, Y.; Wong, K.S.; Wang, Y.; et al. Prediction of recurrent stroke or transient ischemic attack after noncardiogenic posterior circulation ischemic stroke. Stroke 2017, 48, 1835–1841. [Google Scholar] [CrossRef] [PubMed]
- Cook, D.; Guyatt, G. Prophylaxis against upper gastrointestinal bleeding in hospitalized patients. N. Engl. J. Med. 2018, 378, 2506–2516. [Google Scholar] [CrossRef] [Green Version]
- Alqudah, M.A.; Al-Azzam, S.; Alzoubi, K.; Alkhatatbeh, M.; Rawashdeh, N. Overuse of proton pump inhibitors for stress ulcer prophylaxis in Jordan. Int. J. Clin. Pharmacol. Ther. 2016, 54, 597–602. [Google Scholar] [CrossRef]
- Ntaios, G.; Chatzinikolaou, A.; Kaiafa, G.; Savopoulos, C.; Hatzitolios, A.; Karamitsos, D. Evaluation of use of proton pump inhibitors in Greece. Eur. J. Intern. Med. 2009, 20, 171–173. [Google Scholar] [CrossRef]
- Savarino, V.; Marabotto, E.; Zentilin, P.; Furnari, M.; Bodini, G.; De Maria, C.; Pellegatta, G.; Coppo, C.; Savarino, E. Proton pump inhibitors: Use and misuse in the clinical setting. Expert Rev. Clin. Pharmacol. 2018, 11, 1123–1134. [Google Scholar] [CrossRef] [PubMed]
- Xie, Y.; Bowe, B.; Yan, Y.; Xian, H.; Li, T.; Al-Aly, Z. Estimates of all cause mortality and cause specific mortality associated with proton pump inhibitors among US veterans: Cohort study. BMJ 2019, 365, l1580. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Yepuri, G.; Sukhovershin, R.; Nazari-Shafti, T.Z.; Petrascheck, M.; Ghebre, Y.T.; Cooke, J.P. Proton Pump inhibitors accelerate endothelial senescence. Circ. Res. 2016, 118, e36–e42. [Google Scholar] [CrossRef] [Green Version]
- Ghebremariam, Y.T.; LePendu, P.; Lee, J.C.; Erlanson, D.A.; Slaviero, A.; Shah, N.H.; Leiper, J.; Cooke, J.P. Unexpected effect of proton pump inhibitors: Elevation of the cardiovascular risk factor asymmetric dimethylarginine. Circulation 2013, 128, 845–853. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Taffi, R.; Nanetti, L.; Mazzanti, L.; Bartolini, M.; Vignini, A.; Raffaelli, F.; Pasqualetti, P.; Vernieri, F.; Provinciali, L.; Silvestrini, M. Plasma levels of nitric oxide and stroke outcome. J. Neurol. 2008, 255, 94–98. [Google Scholar] [CrossRef] [PubMed]
- Teh, W.H.; Smith, C.J.; Barlas, R.S.; Wood, A.D.; Bettencourt-Silva, J.H.; Clark, A.B.; Metcalf, A.K.; Bowles, K.M.; Potter, J.F.; Myint, P.K. Impact of stroke-associated pneumonia on mortality, length of hospitalization, and functional outcome. Acta Neurol. Scand. 2018, 138, 293–300. [Google Scholar] [CrossRef] [Green Version]
- Marchina, S.; Doros, G.; Modak, J.; Helenius, J.; Aycock, D.M.; Kumar, S. Acid-suppressive medications and risk of pneumonia in acute stroke patients: A systematic review and meta-analysis. J. Neurol. Sci. 2019, 400, 122–128. [Google Scholar] [CrossRef]
- Bardou, M.; Quenot, J.P.; Barkun, A. Stress-related mucosal disease in the critically ill patient. Nat. Rev. Gastroenterol. Hepatol. 2015, 12, 98–107. [Google Scholar] [CrossRef]
- Garcia Rodriguez, L.A.; Lin, K.J.; Hernandez-Diaz, S.; Johansson, S. Risk of upper gastrointestinal bleeding with low-dose acetylsalicylic acid alone and in combination with clopidogrel and other medications. Circulation 2011, 123, 1108–1115. [Google Scholar] [CrossRef] [Green Version]
- Wang, T.; Zhu, D.; Kong, L.; Mu, C.; Li, C.; Hu, L. Effect of upper gastrointestinal bleeding on prognosis of middle-aged patients with acute ischemic stroke: A retrospective study. Ann. Palliat. Med. 2021, 10, 5494–5501. [Google Scholar] [CrossRef]
- Chou, Y.F.; Weng, W.C.; Huang, W.Y. Association between gastrointestinal bleeding and 3-year mortality in patients with acute, first-ever ischemic stroke. J. Clin. Neurosci. 2017, 44, 289–293. [Google Scholar] [CrossRef]
- Rumalla, K.; Mittal, M.K. Gastrointestinal bleeding in acute ischemic stroke: A population-based analysis of hospitalizations in the United States. J. Stroke Cerebrovasc. Dis. 2016, 25, 1728–1735. [Google Scholar] [CrossRef]
- Ji, R.; Shen, H.; Pan, Y.; Wang, P.; Liu, G.; Wang, Y.; Li, H.; Singhal, A.B.; Wang, Y.; China National Stroke Registry (CNSR) investigators. Risk score to predict gastrointestinal bleeding after acute ischemic stroke. BMC Gastroenterol. 2014, 14, 130. [Google Scholar] [CrossRef] [Green Version]
- Fu, J. Factors affecting the occurrence of gastrointestinal bleeding in acute ischemic stroke patients. Medicine 2019, 98, e16312. [Google Scholar] [CrossRef] [PubMed]
- Du, W.; Zhao, X.; Wang, Y.; Pan, Y.; Liu, G.; Wang, A.; Ji, R.; Liu, L.; Gu, H.; Dong, K.; et al. Gastrointestinal bleeding during acute ischaemic stroke hospitalisation increases the risk of stroke recurrence. Stroke Vasc. Neurol. 2020, 5, 116–120. [Google Scholar] [CrossRef] [PubMed]
- Chang, H.; Wang, X.; Yang, X.; Song, H.; Qiao, Y.; Liu, J. Digestive and urologic hemorrhage after intravenous thrombolysis for acute ischemic stroke: Data from a Chinese stroke center. J. Int. Med. Res. 2017, 45, 352–360. [Google Scholar] [CrossRef] [PubMed]
Figure 1.
Flow chart of patient selection. mRS: modified Rankin scale; PPIs: proton pump inhibitors; Non-PPI: Non-proton pump inhibitors.
Figure 1.
Flow chart of patient selection. mRS: modified Rankin scale; PPIs: proton pump inhibitors; Non-PPI: Non-proton pump inhibitors.
Figure 2.
Forest plots for a poor outcome at one year in patients with different baseline characteristics.
Figure 2.
Forest plots for a poor outcome at one year in patients with different baseline characteristics.
Table 1.
Demographic and clinical characteristics of the study population.
| Variables | Unmatched | p Value | Propensity-Matched | p Value | ||
|---|---|---|---|---|---|---|
| PPI Prophylaxis (n = 3335) | Non-PPI Prophylaxis (n = 1207) | PPI Prophylaxis (n = 1207) | Non-PPI Prophylaxis (n = 1207) | |||
| Age, years | 67.3 ± 12.9 | 68.3 ± 12.3 | 0.020 | 68.2 ± 12.5 | 68.3 ± 12.3 | 0.763 |
| Female | 1311 (39.3) | 472 (39.1) | 0.918 | 501 (41.5) | 472 (39.1) | 0.245 |
| Risk factors | ||||||
| History of smoking | 1244 (37.3) | 411 (34.1) | 0.047 | 403 (33.4) | 411 (34.1) | 0.763 |
| History of stroke | 609 (18.3) | 227 (18.8) | 0.697 | 218 (18.1) | 227 (18.8) | 0.675 |
| Hypertension | 2489(74.6) | 907 (75.1) | 0.757 | 910 (75.4) | 907 (75.1) | 0.925 |
| Diabetes mellitus | 1027 (30.8) | 370 (30.7) | 0.942 | 345 (28.6) | 370 (30.7) | 0.285 |
| Atrial fibrillation | 483 (14.5) | 159 (13.2) | 0.268 | 156 (12.9) | 159 (13.2) | 0.904 |
| Hyperlipidemia | 335 (10.0) | 155 (12.8) | 0.008 | 150 (12.4) | 155 (12.8) | 0.806 |
| Clinical variables | ||||||
| Baseline NIHSS | 3 (1–6) | 2 (1–4) | <0.001 | 2 (1–4) | 2 (1–4) | 0.789 |
| Baseline SBP, mmHg | 150.5 ± 22.9 | 150.8 ± 23.1 | 0.770 | 150.8 ± 23.0 | 150.8 ± 23.1 | 0.950 |
| Baseline DBP, mmHg | 84.2 ± 13.7 | 84.8 ± 26.2 | 0.271 | 84.1 ± 13.6 | 84.2 ± 13.4 | 0.921 |
| Blood glucose, mmol/L | 6.00 ± 2.17 | 6.12 ± 2.33 | 0.124 | 5.84 ± 2.00 | 6.12 ± 2.33 | 0.002 |
| Intravenous thrombolysis | 286 (8.6) | 100 (8.3) | 0.810 | 71 (5.9) | 100 (8.3) | 0.026 |
| Outcome | ||||||
| Poor outcome at discharge | 1213 (36.4) | 348 (28.8) | <0.001 | 370 (30.7) | 348 (28.8) | 0.350 |
| Poor outcome at 1 year | 1109 (33.3) | 312 (25.8) | <0.001 | 373 (30.9) | 312 (25.8) | 0.007 |
| All-cause death | 359 (10.8) | 106 (8.8) | 0.053 | 117 (9.7) | 106 (8.8) | 0.482 |
| Stroke event | 220 (7.4) | 76 (6.9) | 0.634 | 86 (7.9) | 76 (6.9) | 0.414 |
| Recurrent ischemic stroke | 213 (7.2) | 76 (6.9) | 0.837 | 81 (7.4) | 76 (6.9) | 0.679 |
| Gastrointestinal bleeding | 51 (1.5) | 1 (0.1) | <0.001 | 19 (1.6) | 1 (0.1) | <0.001 |
| Post-stroke pneumonia | 466 (14.0) | 98 (8.1) | <0.001 | 137 (11.4) | 98 (8.1) | 0.009 |
PPIs: proton pump inhibitors, NIHSS: national institutes of health stroke scale, SBP: systolic blood pressure, DBP: diastolic blood pressure.
Table 2.
Univariate comparison and multivariate analysis for poor outcome at one year in unmatched and propensity-matched patients.
Table 2.
Univariate comparison and multivariate analysis for poor outcome at one year in unmatched and propensity-matched patients.
| Variables | Unmatched | Propensity-Matched | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Univariate Analysis | Multivariate Analysis | Univariate Analysis | Multivariate Analysis | |||||||
| Poor Outcome (n = 1421) | Good Outcome (n = 3121) | p Value | OR (95% CI) | p Value | Poor Outcome (n = 685) | Good Outcome (n = 1729) | p Value | OR (95% CI) | p Value | |
| Age, years | 75.0 ± 10.9 | 64.3 ± 12.1 | <0.001 | 1.091 (1.082–1.100) | <0.001 | 75.9 ± 10.5 | 65.2 ± 11.8 | <0.001 | 1.095 (1.083–1.108) | <0.001 |
| Female | 673 (47.4) | 1110 (35.6) | <0.001 | 1.293 (1.068–1.566) | 0.008 | 325 (47.4) | 648 (37.5) | <0.001 | 1.172 (0.904–1.518) | 0.232 |
| Risk factors | ||||||||||
| History of smoking | 421 (29.6) | 1234 (39.5) | <0.001 | 1.151 (0.940–1.410) | 0.174 | 184 (26.9) | 630 (36.4) | <0.001 | 1.120 (0.843–1.489) | 0.435 |
| History of stroke | 396 (27.9) | 440 (14.1) | <0.001 | 2.052 (1.699–2.478) | <0.001 | 188 (27.4) | 257 (14.9) | <0.001 | 1.771 (1.368–2.293) | <0.001 |
| Hypertension | 1126 (79.2) | 2270 (72.7) | <0.001 | 1.126 (0.929–1.364) | 0.227 | 559 (81.6) | 1258 (72.8) | <0.001 | 1.317 (1.002–1.730) | 0.049 |
| Diabetes mellitus | 491 (34.6) | 906 (29.0) | 0.001 | 1.658 (1.400–1.964) | <0.001 | 234 (34.2) | 481 (27.8) | 0.003 | 1.847 (1.458–2.339) | <0.001 |
| Atrial fibrillation | 368 (25.9) | 274 (8.8) | <0.001 | 1.155 (0.923–1.447) | 0.208 | 152 (22.2) | 163 (9.4) | <0.001 | 1.139 (0.836–1.553) | 0.410 |
| Hyperlipidemia | 110 (7.7) | 380 (12.2) | <0.001 | 0.862 (0.660–1.126) | 0.277 | 68 (9.9) | 237 (13.7) | 0.012 | 0.922 (0.656–1.296) | 0.639 |
| Clinical variables | ||||||||||
| Baseline NIHSS | 6 (3–11) | 2 (1–4) | <0.001 | 1.260 (1.235–1.285) | <0.001 | 4 (2–9) | 2 (1–3) | <0.001 | 1.295 (1.253–1.338) | <0.001 |
| Baseline SBP, mmHg | 152.5 ± 23.7 | 149.7 ± 22.6 | <0.001 | NA | NA | 153.0 ± 23.2 | 149.8 ± 22.9 | 0.003 | NA | NA |
| Baseline DBP, mmHg | 82.4 ± 13.5 | 85.0 ± 13.5 | <0.001 | NA | NA | 82.9 ± 13.3 | 84.7 ± 13.5 | 0.003 | NA | NA |
| Blood glucose, mmol/L | 6.43 ± 2.56 | 5.85 ± 2.01 | <0.001 | NA | NA | 6.28 ± 2.47 | 5.86 ± 2.03 | <0.001 | NA | NA |
| Intravenous thrombolysis | 138 (9.7) | 248 (7.9) | 0.051 | NA | NA | 50 (7.3) | 121 (7.0) | 0.792 | NA | NA |
| PPI prophylaxis | 1109 (78.0) | 2226 (71.3) | <0.001 | 1.321 (1.102–1.584) | 0.003 | 373 (54.5) | 834 (48.2) | 0.007 | 1.432 (1.151–1.780) | 0.001 |
Values are mean (SD), median (interquartile range), or No. (%) as appropriate. PPIs: proton pump inhibitors, NIHSS: national institutes of health stroke scale, SBP: systolic blood pressure, DBP: Diastolic blood pressure.
Table 3.
Univariate comparison and multivariate analysis for poor outcome at one year between AIS patients with PPI prophylaxis more than seven days and less than seven days.
Table 3.
Univariate comparison and multivariate analysis for poor outcome at one year between AIS patients with PPI prophylaxis more than seven days and less than seven days.
| Variables | Univariate Analysis | Multivariate Analysis | |||
|---|---|---|---|---|---|
| Poor Outcome (n = 1421) | Good Outcome (n = 3121) | p Value | OR (95% CI) | p Value | |
| Age, years | 75.0 ± 10.9 | 64.3 ± 12.1 | <0.001 | 1.091 (1.082–1.100) | <0.001 |
| Female, n (%) | 673 (47.4) | 1110 (35.6) | <0.001 | 1.298 (1.072–1.571) | 0.007 |
| Risk factors | |||||
| History of smoking | 421 (29.6) | 1234 (39.5) | <0.001 | 1.153 (0.940–1.410) | 0.170 |
| History of stroke | 396 (27.9) | 440 (14.1) | <0.001 | 2.046 (1.695–2.470) | <0.001 |
| Hypertension | 1126 (79.2) | 2270 (72.7) | <0.001 | 1.130 (0.932–1.369) | 0.213 |
| Diabetes mellitus | 491 (34.6) | 906 (29.0) | 0.001 | 1.656 (1.399–1.962) | <0.001 |
| Atrial fibrillation | 368 (25.9) | 274 (8.8) | <0.001 | 1.161 (0.928–1.454) | 0.192 |
| Hyperlipidemia | 110 (7.7) | 380 (12.2) | <0.001 | 0.849 (0.650–1.109) | 0.231 |
| Clinical variables | |||||
| Baseline NIHSS | 6 (3–11) | 2 (1–4) | <0.001 | 1.260 (1.234–1.285) | <0.001 |
| Baseline SBP, mmHg | 152.5 ± 23.7 | 149.7 ± 22.6 | <0.001 | NA | NA |
| Baseline DBP, mmHg | 82.4 ± 13.5 | 85.0 ± 13.5 | <0.001 | NA | NA |
| Blood glucose, mmol/L | 6.43 ± 2.56 | 5.85 ± 2.01 | <0.001 | NA | NA |
| Intravenous thrombolysis | 138 (9.7) | 248 (7.9) | 0.051 | NA | NA |
| PPI prophylaxis | 890 (62.6) | 1707 (54.7) | <0.001 | 1.181 (1.006–1.388) | 0.042 |
Values are mean (SD), median (interquartile range), or No. (%) as appropriate. PPIs: proton pump inhibitors, NIHSS: national institutes of health stroke scale, SBP: systolic blood pressure, DBP: diastolic blood pressure.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
MDPI and ACS Style
Fang, L.; Zhong, W.; Gong, X.; Chen, Z.; Chen, Y.; Yan, S.; Lou, M. Association of Proton Pump Inhibitor Prophylaxis on Clinical Outcome in Acute Ischemic Stroke in China: A Multicenter Retrospective Cohort Study. J. Clin. Med. 2022, 11, 6881. https://doi.org/10.3390/jcm11236881
AMA Style
Fang L, Zhong W, Gong X, Chen Z, Chen Y, Yan S, Lou M. Association of Proton Pump Inhibitor Prophylaxis on Clinical Outcome in Acute Ischemic Stroke in China: A Multicenter Retrospective Cohort Study. Journal of Clinical Medicine. 2022; 11(23):6881. https://doi.org/10.3390/jcm11236881
Chicago/Turabian StyleFang, Lei, Wansi Zhong, Xiaoxian Gong, Zhicai Chen, Yi Chen, Shenqiang Yan, and Min Lou. 2022. "Association of Proton Pump Inhibitor Prophylaxis on Clinical Outcome in Acute Ischemic Stroke in China: A Multicenter Retrospective Cohort Study" Journal of Clinical Medicine 11, no. 23: 6881. https://doi.org/10.3390/jcm11236881
APA StyleFang, L., Zhong, W., Gong, X., Chen, Z., Chen, Y., Yan, S., & Lou, M. (2022). Association of Proton Pump Inhibitor Prophylaxis on Clinical Outcome in Acute Ischemic Stroke in China: A Multicenter Retrospective Cohort Study. Journal of Clinical Medicine, 11(23), 6881. https://doi.org/10.3390/jcm11236881
Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.
